Todd Bazemore's most recent trade in Kala Pharmaceuticals Inc was a trade of 47,768 Common Stock done at an average price of $0.8 . Disclosure was reported to the exchange on Oct. 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kala Pharma Inc | Todd Bazemore | Director | 22 Oct 2025 | 47,768 | 35,932 (0%) | 0% | 0.8 | 39,647 | Common Stock | |
| Kala Pharma Inc | Todd Bazemore | Director, SEE REMARKS | 29 Aug 2025 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | ||
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 24 Jun 2025 | 4,058 | 83,699 (0%) | 0% | 4.0 | 16,273 | Common Stock | |
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 03 Jun 2025 | 3,390 | 87,757 (0%) | 0% | 3.7 | 12,679 | Common Stock | |
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 07 Mar 2025 | 45,200 | 45,200 | - | - | Stock Option (right to buy) | ||
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 06 Jan 2025 | 45,200 | 45,200 | - | - | Stock Option (right to buy) | ||
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 06 Jan 2025 | 10,100 | - | 0% | 0 | Common Stock | ||
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 06 Jan 2025 | 1,993 | - | 0% | 7.6 | 15,207 | Common Stock | |
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 26 Jun 2024 | 4,653 | 83,040 (0%) | 0% | 4.8 | 22,102 | Common Stock | |
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 31 May 2024 | 2,093 | 87,693 (0%) | 0% | 6.1 | 12,746 | Common Stock | |
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 04 Jan 2024 | 29,300 | 29,300 | - | - | Stock Option (right to buy) | ||
| Kala Pharma Inc | Bazemore Todd | SEE REMARKS | 04 Jan 2024 | 6,500 | - | 0% | 0 | Common Stock | ||
| Kala Pharma Inc | Bazemore Todd | SEE REMARKS | 04 Jan 2024 | 1,405 | - | 0% | 6.7 | 9,470 | Common Stock | |
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 14 Mar 2023 | 576 | 576 | - | - | Stock Option (Right to Buy) | ||
| Pulmatrix Inc | Todd Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 1,700 | 1,700 | - | - | Stock Option (Right to Buy) | |
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 04 Jan 2023 | 12,800 | 14,897 (0%) | 0% | 0 | Common Stock | ||
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 04 Jan 2023 | 62 | 14,835 (0%) | 0% | 28.5 | 1,769 | Common Stock | |
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 26 Oct 2022 | 214 | 2,097 (0%) | 0% | 6.5 | 1,393 | Common Stock | |
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 27 Jun 2022 | 3,092 | 115,499 (0%) | 0% | 0.4 | 1,144 | Common Stock | |
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 03 Jan 2022 | 238,000 | 238,000 | - | - | Stock Option (right to buy) | ||
| Kala Pharma Inc | Todd Bazemore | SEE REMARKS | 03 Jan 2022 | 3,454 | 118,591 (0%) | 0% | 1.3 | 4,490 | Common Stock | |
| Kala Pharma Inc | Todd Bazemore | CHIEF OPERATING OFFICER | 26 Oct 2021 | 12,544 | 122,045 (0%) | 0% | 1.8 | 22,579 | Common Stock |